{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:50:14Z","timestamp":1760205014611,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R25MH071584","MH61019-02"],"award-info":[{"award-number":["R25MH071584","MH61019-02"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA12382-01"],"award-info":[{"award-number":["DA12382-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R03 AA11413-02"],"award-info":[{"award-number":["R03 AA11413-02"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00213-019-05235-x","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T16:56:11Z","timestamp":1553705771000},"page":"2635-2640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysis"],"prefix":"10.1007","volume":"236","author":[{"given":"Swapnil","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7357-8215","authenticated-orcid":false,"given":"Joao P.","family":"De Aquino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak C.","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohini","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"key":"5235_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1017\/S0033291717001209","volume":"48","author":"M Aas","year":"2018","unstructured":"Aas M, Melle I, Bettella F, Djurovic S, Le Hellard S, Bjella T, Ringen P, Lagerberg T, Smeland O, Agartz I (2018) Psychotic patients who used cannabis frequently before illness onset have higher genetic predisposition to schizophrenia than those who did not. Psychol Med 48:43\u201349","journal-title":"Psychol Med"},{"key":"5235_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1124\/pr.110.002642","volume":"63","author":"J-M Beaulieu","year":"2011","unstructured":"Beaulieu J-M, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63:182\u2013217","journal-title":"Pharmacol Rev"},{"key":"5235_CR3","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.biopsych.2013.05.027","volume":"75","author":"MA Bloomfield","year":"2014","unstructured":"Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD (2014) Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 75:470\u2013478","journal-title":"Biol Psychiatry"},{"key":"5235_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nature20153","volume":"539","author":"MA Bloomfield","year":"2016","unstructured":"Bloomfield MA, Ashok AH, Volkow ND, Howes OD (2016) The effects of delta(9)-tetrahydrocannabinol on the dopamine system. Nature 539:369\u2013377","journal-title":"Nature"},{"key":"5235_CR5","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1007\/s00213-015-3915-0","volume":"232","author":"MG Bossong","year":"2015","unstructured":"Bossong MG, Mehta MA, van Berckel BN, Howes OD, Kahn RS, Stokes PR (2015) Further human evidence for striatal dopamine release induced by administration of\u2206 9-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology 232:2723\u20132729","journal-title":"Psychopharmacology"},{"key":"5235_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1024465317902","volume":"11","author":"JD Bremner","year":"1998","unstructured":"Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM (1998) Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). J Trauma Stress 11:125\u2013136","journal-title":"J Trauma Stress"},{"key":"5235_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0014-2999(90)94136-L","volume":"190","author":"J Chen","year":"1990","unstructured":"Chen J, Paredes W, Lowinson JH, Gardner EL (1990) Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. Eur J Pharmacol 190:259\u2013262","journal-title":"Eur J Pharmacol"},{"key":"5235_CR8","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","volume":"57","author":"DC D\u2019Souza","year":"2005","unstructured":"D\u2019Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57:594\u2013608","journal-title":"Biol Psychiatry"},{"key":"5235_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00213-007-1042-2","volume":"198","author":"DC D'Souza","year":"2008","unstructured":"D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, Ranganathan M, Bhakta S, Zimolo Z, Cooper T, Perry E (2008) Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of delta-9-tetrahydrocannabinol in humans. Psychopharmacology 198:587\u2013603","journal-title":"Psychopharmacology"},{"key":"5235_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pnpbp.2011.12.005","volume":"38","author":"MA El Khoury","year":"2012","unstructured":"El Khoury MA, Gorgievski V, Moutsimilli L, Giros B, Tzavara ET (2012) Interactions between the cannabinoid and dopaminergic systems: evidence from animal studies. Prog Neuro-Psychopharmacol Biol Psychiatry 38:36\u201350","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"5235_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0269881112460109","volume":"27","author":"A Englund","year":"2013","unstructured":"Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 27:19\u201327","journal-title":"J Psychopharmacol"},{"key":"5235_CR12","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1111\/j.1755-5949.2010.00144.x","volume":"16","author":"J Fernandez-Ruiz","year":"2010","unstructured":"Fernandez-Ruiz J, Hernandez M, Ramos JA (2010) Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16:e72\u2013e91","journal-title":"CNS Neurosci Ther"},{"unstructured":"First MB, Gibbon M (2004) The structured clinical interview for DSM-IV axis I disorders (SCID-I) and the structured clinical interview for DSM-IV axis II disorders (SCID-II)","key":"5235_CR13"},{"key":"5235_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0304-3940(97)00278-4","volume":"226","author":"ED French","year":"1997","unstructured":"French ED (1997) delta9-tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett 226:159\u2013162","journal-title":"Neurosci Lett"},{"key":"5235_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00001756-199702100-00014","volume":"8","author":"ED French","year":"1997","unstructured":"French ED, Dillon K, Wu X (1997) Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 8:649\u2013652","journal-title":"Neuroreport"},{"key":"5235_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.pbb.2005.01.032","volume":"81","author":"EL Gardner","year":"2005","unstructured":"Gardner EL (2005) Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 81:263\u2013284","journal-title":"Pharmacol Biochem Behav"},{"key":"5235_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0014-2999(97)01442-8","volume":"341","author":"GL Gessa","year":"1998","unstructured":"Gessa GL, Melis M, Muntoni AL, Diana M (1998) Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 341:39\u201344","journal-title":"Eur J Pharmacol"},{"key":"5235_CR18","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1523\/JNEUROSCI.17-14-05327.1997","volume":"17","author":"M Glass","year":"1997","unstructured":"Glass M, Felder CC (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17:5327\u20135333","journal-title":"J Neurosci"},{"key":"5235_CR19","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/schbul\/sbn108","volume":"34","author":"C Henquet","year":"2008","unstructured":"Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM (2008) Gene-environment interplay between cannabis and psychosis. Schizophr Bull 34:1111\u20131121","journal-title":"Schizophr Bull"},{"key":"5235_CR20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0306-4522(01)00509-7","volume":"109","author":"H Hermann","year":"2002","unstructured":"Hermann H, Marsicano G, Lutz B (2002) Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109:451\u2013460","journal-title":"Neuroscience"},{"key":"5235_CR21","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0140-6736(13)62036-X","volume":"383","author":"OD Howes","year":"2014","unstructured":"Howes OD, Murray RM (2014) Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet 383:1677\u20131687","journal-title":"Lancet"},{"key":"5235_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.biopsych.2016.07.014","volume":"81","author":"OD Howes","year":"2017","unstructured":"Howes OD, McCutcheon R, Owen MJ, Murray RM (2017) The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry 81:9\u201320","journal-title":"Biol Psychiatry"},{"key":"5235_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0306-4522(03)00070-8","volume":"119","author":"MD Julian","year":"2003","unstructured":"Julian MD, Martin AB, Cuellar B, Rodriguez De Fonseca F, Navarro M, Moratalla R, Garcia-Segura LM (2003) Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience 119:309\u2013318","journal-title":"Neuroscience"},{"key":"5235_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261\u2013276","journal-title":"Schizophr Bull"},{"key":"5235_CR25","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1124\/mol.104.006882","volume":"67","author":"CS Kearn","year":"2005","unstructured":"Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M (2005) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol 67:1697\u20131704","journal-title":"Mol Pharmacol"},{"key":"5235_CR26","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1177\/0269881112446534","volume":"26","author":"D Kleinloog","year":"2012","unstructured":"Kleinloog D, Liem-Moolenaar M, Jacobs G, Klaassen E, de Kam M, Hijman R, van Gerven J (2012) Does olanzapine inhibit the psychomimetic effects of \u03949-tetrahydrocannabinol? J Psychopharmacol 26:1307\u20131316","journal-title":"J Psychopharmacol"},{"key":"5235_CR27","doi-asserted-by":"publisher","first-page":"e70378","DOI":"10.1371\/journal.pone.0070378","volume":"8","author":"R Kuepper","year":"2013","unstructured":"Kuepper R, Ceccarini J, Lataster J, van Os J, van Kroonenburgh M, van Gerven JM, Marcelis M, Van Laere K, Henquet C (2013) Delta-9-tetrahydrocannabinol-induced dopamine release as a function of psychosis risk: 18F-fallypride positron emission tomography study. PLoS One 8:e70378","journal-title":"PLoS One"},{"key":"5235_CR28","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s00018-006-6027-5","volume":"63","author":"SR Laviolette","year":"2006","unstructured":"Laviolette SR, Grace AA (2006) The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci 63:1597\u20131613","journal-title":"Cell Mol Life Sci"},{"key":"5235_CR29","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1177\/0269881109358200","volume":"24","author":"M Liem-Moolenaar","year":"2010","unstructured":"Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, Touw D, van Gerven JM (2010) Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol 24:1697\u20131708","journal-title":"J Psychopharmacol"},{"key":"5235_CR30","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/sj.bjp.0705478","volume":"140","author":"G Marchese","year":"2003","unstructured":"Marchese G, Casti P, Ruiu S, Saba P, Sanna A, Casu G, Pani L (2003) Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications. Br J Pharmacol 140:520\u2013526","journal-title":"Br J Pharmacol"},{"key":"5235_CR31","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S0028-3908(01)00012-0","volume":"40","author":"JP Meschler","year":"2001","unstructured":"Meschler JP, Howlett AC (2001) Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology 40:918\u2013926","journal-title":"Neuropharmacology"},{"key":"5235_CR32","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0091-3057(00)00390-7","volume":"67","author":"JP Meschler","year":"2000","unstructured":"Meschler JP, Conley TJ, Howlett AC (2000) Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity. Pharmacol Biochem Behav 67:567\u2013573","journal-title":"Pharmacol Biochem Behav"},{"key":"5235_CR33","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0892-0362(98)00061-0","volume":"21","author":"JS Meyer","year":"1999","unstructured":"Meyer JS, Kunkle R (1999) Behavioral responses to a D1 dopamine agonist in weanling rats treated neonatally with cocaine and delta9-tetrahydrocannabinol. Neurotoxicol Teratol 21:375\u2013380","journal-title":"Neurotoxicol Teratol"},{"key":"5235_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hup.1166","volume":"26","author":"P Morrison","year":"2011","unstructured":"Morrison P, Stone J (2011) Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation. Hum Psychopharmacol Clin Exp 26:77\u201380","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"5235_CR35","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.pbb.2006.05.018","volume":"84","author":"H Nagai","year":"2006","unstructured":"Nagai H, Egashira N, Sano K, Ogata A, Mizuki A, Mishima K, Iwasaki K, Shoyama Y, Nishimura R, Fujiwara M (2006) Antipsychotics improve delta9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice. Pharmacol Biochem Behav 84:330\u2013336","journal-title":"Pharmacol Biochem Behav"},{"key":"5235_CR36","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/jnnp.2005.079228","volume":"77","author":"S Potvin","year":"2006","unstructured":"Potvin S, Pampoulova T, Mancini-Marie A, Lipp O, Bouchard R, Stip E (2006) Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiatry 77:796\u2013798","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5235_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0304-3940(96)12436-8","volume":"206","author":"MC Sanudo-Pena","year":"1996","unstructured":"Sanudo-Pena MC, Patrick SL, Patrick RL, Walker JM (1996) Effects of intranigral cannabinoids on rotational behavior in rats: interactions with the dopaminergic system. Neurosci Lett 206:21\u201324","journal-title":"Neurosci Lett"},{"key":"5235_CR38","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/(SICI)1098-2396(199810)30:2<221::AID-SYN12>3.0.CO;2-4","volume":"30","author":"MC Sanudo-Pena","year":"1998","unstructured":"Sanudo-Pena MC, Force M, Tsou K, Miller AS, Walker JM (1998) Effects of intrastriatal cannabinoids on rotational behavior in rats: interactions with the dopaminergic system. Synapse (New York, NY) 30:221\u2013226","journal-title":"Synapse (New York, NY)"},{"unstructured":"Sobell LC, Sobell MB (1992) Timeline follow-back Measuring alcohol consumption. Springer, pp 41\u201372","key":"5235_CR39"},{"key":"5235_CR40","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1126\/science.276.5321.2048","volume":"276","author":"G Tanda","year":"1997","unstructured":"Tanda G, Pontieri FE, Di Chiara G (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science (New York, NY) 276:2048\u20132050","journal-title":"Science (New York, NY)"},{"key":"5235_CR41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.brainres.2004.06.033","volume":"1020","author":"AN Verty","year":"2004","unstructured":"Verty AN, McGregor IS, Mallet PE (2004) The dopamine receptor antagonist SCH 23390 attenuates feeding induced by delta9-tetrahydrocannabinol. Brain Res 1020:188\u2013195","journal-title":"Brain Res"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-019-05235-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-019-05235-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-019-05235-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T09:19:13Z","timestamp":1589620753000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-019-05235-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["5235"],"URL":"https:\/\/doi.org\/10.1007\/s00213-019-05235-x","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"type":"print","value":"0033-3158"},{"type":"electronic","value":"1432-2072"}],"subject":[],"published":{"date-parts":[[2019,3,27]]},"assertion":[{"value":"16 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DCD has received in the past 3\u00a0years and currently receives research grant support administered through Yale University School of Medicine from Pfizer Inc. All other authors report no biomedical financial interests or potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}